INCY
Incyte CorporationNASDAQ
Healthcare • Biotechnology
Factor tilt: Large-Cap Defensive
$119.65+1.39%
Close Nov 6, 2026
- Market cap
- $23.9B
- 1 month
- +6.1%
- 3 months
- -1.6%
- 1 year
- +13.2%
- 52-week range
- $90.30$129.93
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$3.87Quarter to Sep 30, 2026 · 16 analysts · revenue $1.46B · -6.7% in 30d
- Short interest
- 5.9% of float10M shares · settled Oct 15, 2026 · +0.4% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $5.82B
- Net income
- $1.61B
- Free cash flow
- $1.92B
- Book value
- $6.34B
- Total debt
- $38.27M
- P/E
- 14.8×
- Price / sales
- 4.1×
- Price / book
- 3.8×
- FCF yield
- +8.0%
- Net margin
- +27.7%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Read more
The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Website
- incyte.com
- Headquarters
- Wilmington, DE, United States
- Employees
- 2,844
- Listed
- Nov 4, 1993
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 31, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Jul 28, 2026 | $1.7B | +37.7% | 93.7% | $697.9M | $585.6M |
| Mar 2026filed Apr 28, 2026 | $1.3B | +20.9% | 91.8% | $324.2M | $303.3M |
| Dec 2025filed Feb 10, 2026 | $1.5B | +27.8% | 92.0% | $384.0M | $299.3M |
| Sep 2025filed Oct 28, 2025 | $1.4B | +20.0% | 92.8% | $431.3M | $424.2M |
| Jun 2025filed Jul 29, 2025 | $1.2B | +16.5% | 93.5% | $310.8M | $405.0M |
| Mar 2025filed Apr 29, 2025 | $1.1B | +19.5% | 93.0% | $216.7M | $158.2M |
| Dec 2024filed Feb 10, 2025 | $1.2B | +16.3% | 92.5% | $297.4M | $201.2M |
| Sep 2024filed Oct 29, 2024 | $1.1B | +23.8% | 92.4% | $146.1M | $106.5M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 10, 2026 | $5.1B | +21.2% | 92.8% | $1.3B | $1.3B |
| Dec 2024filed Feb 10, 2025 | $4.2B | +14.8% | 92.6% | $101.3M | $32.6M |
| Dec 2023filed Feb 13, 2024 | $3.7B | +8.9% | 93.1% | $655.4M | $597.6M |
| Dec 2022filed Feb 7, 2023 | $3.4B | +13.7% | 93.9% | $591.6M | $340.7M |
| Dec 2021filed Feb 8, 2022 | $3.0B | +12.0% | 94.9% | $585.8M | $948.6M |
| Dec 2020filed Feb 9, 2021 | $2.7B | +23.5% | 95.1% | -$263.7M | -$295.7M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched INCY. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
10,025,354 shares short
+38,270 shares (+0.4%) vs Sep 30, 2026
5.9% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
9,987,084 shares short
+5,715 shares (+0.1%) vs Sep 15, 2026
5.8% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
9,981,369 shares short
+616,682 shares (+6.6%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
9,364,687 shares short
-24,813 shares (-0.3%) vs Aug 14, 2026
5.6% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
9,389,500 shares short
-856,977 shares (-8.4%) vs Jul 31, 2026
5.6% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
10,246,477 shares short
-265,646 shares (-2.5%) vs Jul 15, 2026
6.1% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind INCY’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
2 for 1 · forward split
Effective Sep 1, 2000
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Nov 10, 1997
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if INCY is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
108 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 2 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
862 filers reported a long position in INCY for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
53%
of the 202.9M shares 13-F filers reported
Moves vs Q1 2026
7 added3 trimmed
Net shares held
-1%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | $3.5B · 30.8M shares | 30.8M | +0.1% |
| 2 | BlackRock, Inc. | $2B · 18M shares | 18M | -5% |
| 3 | DODGE & COX | $1.4B · 12M shares | 12M | -2.4% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $1.2B · 11M shares | 11M | +0.9% |
| 5 | STATE STREET CORP | $1.1B · 9.7M shares | 9.7M | +0.8% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | $883.2M · 7.8M shares | 7.8M | +0.4% |
| 7 | AQR CAPITAL MANAGEMENT LLC | $603.2M · 5.3M shares | 5.3M | -8.4% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $536.5M · 4.8M shares | 4.8M | +1% |
| 9 | LSV ASSET MANAGEMENT | $467.5M · 4.1M shares | 4.1M | +5.2% |
| 10 | Invesco Ltd. | $462.6M · 4.1M shares | 4.1M | +5.4% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of INCY file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| May 14, 2026 | DODGE & COX13G · passive · amended | 6.2% |
| May 11, 2026 | BAKER BROS. ADVISORS LP13D · activist · amended | 15.6% |
| Apr 30, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 6.32% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for INCY
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.